CBD in the Treatment of Epilepsy

Molecules. 2024 Apr 25;29(9):1981. doi: 10.3390/molecules29091981.

Abstract

It has been several years since highly purified cannabidiol (CBD) was registered as a medication that can be used in children of at least 2 years of age to treat different types of seizures related to Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and more recently tuberous sclerosis complex (TSC). During this time, 39 randomized clinical trials (RCTs) and 13 meta-analyses on the efficacy and safety of CBD treatment have been published. Each of the meta-analyses had its own criteria for the RCTs' inclusion and, therefore, slightly different interpretations of the analyzed data. Each of them contributed in its own way to the understanding of CBD pharmacology, mechanisms of therapeutic action, development of adverse reactions, and drug-drug interactions. Hence, it seemed reasonable to gather the most relevant data in one article and present all the current knowledge on the use of CBD in epilepsy. The results of the 13 meta-analyses presented herein confirmed the effectiveness and safety of CBD in children and adolescents with DREs. In adults, reliable conclusions cannot be drawn due to insufficient data.

Keywords: CBD; efficacy; epilepsy; phytocannabinoids; safety; seizure.

Publication types

  • Review

MeSH terms

  • Anticonvulsants* / pharmacology
  • Anticonvulsants* / therapeutic use
  • Cannabidiol* / pharmacology
  • Cannabidiol* / therapeutic use
  • Child
  • Epilepsies, Myoclonic / drug therapy
  • Epilepsy* / drug therapy
  • Humans
  • Lennox Gastaut Syndrome / drug therapy
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • Cannabidiol
  • Anticonvulsants